13F Holdings
中文EN

MDXG MIMEDX GROUP, INC.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1376339 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-22.8%
TTM net income YoY-147.0%
TTM EPS YoY-148.1%
Revenue 3-yr CAGR-0.6%
Net income 3-yr CAGR—

Margins

Gross margin77.3%
Operating margin-8.3%
Net margin-6.3%
FCF margin—
EBITDA margin-3.5%

Returns

ROE-8.5%
ROA-6.6%
ROIC (approx.)-19.3%
Asset turnover1.04x

Leverage & solvency

Liabilities / assets20.2%
Debt / equity0.00x
Current ratio4.35x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-1.08x
Accruals ratio-13.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$418.63M$348.88M$321.48M$267.84M$242.02M
Cost of revenue$73.01M$60.07M$54.63M$48.32M$39.63M
Gross profit$345.62M$288.81M$266.84M$219.53M$202.39M
R&D expense$15.10M$12.34M$12.66M$12.70M$9.93M
SG&A expense$266.19M$225.09M$211.12M$208.67M$194.85M
Operating income$63.89M$58.87M$37.12M-$14.73M-$7.05M
Interest expense$1.78M$3.94M$6.58M$5.05M—
Pretax income$66.26M$57.29M$30.63M-$19.75M-$12.05M
Income tax$17.68M$15.30M-$36.81M$206,000$247,000
Net income$48.58M$42.42M$58.23M-$30.20M-$10.29M
EBITDA$78.77M$64.91M$40.54M-$11.38M-$2.69M
EPS (basic)0.330.290.40-0.33-0.15
EPS (diluted)0.320.280.37-0.33-0.15
Weighted avg. shares (diluted)149.72M149.05M145.96M112.91M110.35M
Banking
Net interest income——-$6.46M-$5.02M-$4.98M
Balance sheet
Cash & equivalents$166.12M$104.42M$82.00M$65.95M$87.08M
Receivables$75.71M$55.83M$53.87M$43.08M$40.35M
Inventory$25.34M$23.81M$21.02M$13.18M$11.39M
Current assets$277.47M$191.89M$164.26M$134.20M$148.52M
PP&E, net$4.71M$5.94M$6.97M$7.86M$9.16M
Goodwill$19.44M$19.44M$19.44M$19.44M$19.44M
Intangibles$14.16M$11.63M$5.26M$5.85M$5.38M
Total assets$342.65M$263.92M$239.05M$171.43M$187.93M
Current liabilities$64.27M$45.59M$46.01M$43.56M$42.36M
Short-term debt$1.50M$1.00M$1.00M——
Long-term debt$16.47M$17.83M$48.10M$48.59M$48.13M
Total debt$17.97M$18.83M$49.10M$48.59M$48.13M
Total liabilities$86.11M$70.81M$96.33M$96.92M$95.35M
Shareholders' equity$256.55M$193.11M$142.72M-$17.99M$82,000
Net debt-$148.15M-$85.59M-$32.90M-$17.36M-$38.96M
Shares outstanding148.09M146.93M146.23M113.71M111.93M
Cash flow statement
Operating cash flow$74.00M$66.20M$26.77M-$17.89M-$1.98M
Capital expenditure——$1.99M$1.51M$3.22M
Free cash flow——$24.79M-$19.41M-$5.20M
Investing cash flow-$6.89M-$9.58M-$2.15M-$2.66M-$3.40M
Financing cash flow-$5.41M-$34.20M-$8.57M-$580,000-$3.35M
Depreciation & amortization$14.88M$6.04M$3.43M$3.35M$4.36M
Stock-based compensation$16.40M$16.93M$16.96M$11.33M$14.16M
Share buybacks$0$0$9.52M$0$0

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.